Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | RHEB | Q15382 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.39 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13868225 | 1.00 | NQO2 (0.46) | NQO2ALDH1A1KDM4EMAPTRXFP1 | |
| SCHEMBL30238680 | 1.00 | NQO2 (0.46) | NQO2ALDH1A1KDM4EMAPTRXFP1 | |
| SCHEMBL28456100 | 1.00 | NQO2 (0.46) | NQO2ALDH1A1KDM4EMAPTRXFP1 | |
| SCHEMBL2737345 | 0.85 | NQO2 (0.48) | NQO2ALDH1A1KDM4EMAPTRXFP1 | |
| SCHEMBL3922552 | 0.81 | NQO2 (0.46) | NQO2ALDH1A1KDM4EMAPTRXFP1 | |
| SCHEMBL13868223 | 0.81 | NQO2 (0.46) | NQO2ALDH1A1KDM4EMAPTRXFP1 | |
| SCHEMBL6764470 | 0.79 | RHEB (0.44) | NQO2ALDH1A1KDM4EMAPTRXFP1 | |
| SCHEMBL27429030 | 0.77 | NQO2 (0.42) | NQO2ALDH1A1KDM4EMAPTRXFP1 | |
| SCHEMBL27429031 | 0.77 | NQO2 (0.42) | NQO2ALDH1A1KDM4EMAPTRXFP1 | |
| SCHEMBL3374595 | 0.76 | SLC6A2 (0.45) | NQO2IDO1PNMTHSD11B1TRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524873-B2 | Substituted N-phenylmethyl ethanamines; N-((6-(methyloxy)-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl)methyl)-1-(1-naphthalenyl)ethanamine; parathyroid hormone inhibitors; antisecretory agents; osteoporosis | AMGEN INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20070142381-A1 | Calcium receptor modulating agents | AMGEN INC. | 2007-06-21 | — | — | US | disclosed |
| US-7196102-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20050143426-A1 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. | 2005-06-30 | — | — | US | disclosed |
| US-6908935-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2005-06-21 | — | — | US | disclosed |
| EP-1509497-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | Amgen Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040082625-A1 | Calcium receptor modulating agents | AMGEN INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2003099776-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082625-A1 | Calcium receptor modulating agents | PTH1R, CASR, CALCR | NQO2 3042/4885ALDH1A1 4611/4885KDM4E 3394/4885 |
| US-20070142381-A1 | Calcium receptor modulating agents | PTH1R, CASR, CALCR | NQO2 3126/4885ALDH1A1 4712/4885KDM4E 3448/4885 |
| US-20050143426-A1 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | PTH1R, PTMS, SOST | NQO2 2664/4885ALDH1A1 4417/4885KDM4E 3290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.